Albendazole ameliorates inflammatory response in a rat model of acute mesenteric ischemia reperfusion injury

dc.contributor.authorBadripour, Abolfazl
dc.contributor.authorBehzadi, Mohamad
dc.contributor.authorHassanipour, Amin
dc.contributor.authorAzar, Pasha Reza Shams
dc.contributor.authorRahbar, Alireza
dc.contributor.authorAbbaslou, Zhaleh
dc.contributor.authorDehpour, Ahmadreza
dc.date.accessioned2026-02-06T18:37:18Z
dc.date.issued2022
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractBackground: Acute mesenteric ischemia is known as a life threatening condition. Re-establishment of blood flow in this condition can lead to mesenteric ischemia reperfusion (MIR) injury which is accompanied by inflammatory response. Still, clear blueprint of inflammatory mechanism underlying MIR injury has not been provided. Interestingly, Albendazole has exhibited notable effects on inflammation and cytokine production. In this study, we aimed to evaluate outcomes of MIR injury following pretreatment with Albendazole with respect to assessment of mesenteric inflammation and ischemia threshold. Methods: Male rats were randomly divided into sham operated, vehicle treated, Albendazole 100 mg/kg and Albendazole 200 mg/kg groups. MIR injury was induced by occlusion of superior mesenteric artery for 30 min followed by 120 min of reperfusion. Samples were utilized for assessment of epithelial survival and villous height. Immunohistochemistry study revealed intestinal expression of TNF-alpha and HIF-1-alpha. Gene expression of NF-kappa B/TLR4/TNF-alpha/IL-6 was measured using RTPCR. Also protein levels of inflammatory cytokines in serum and intestine were assessed by ELISA method. Results: Histopathological study demonstrated that pretreatment with Albendazole could ameliorate decline in villous height and epithelial survival following MIR injury. Also, systemic inflammation was suppressed after administration of Albendazole. Analysis of possible participating inflammatory pathway could demonstrate that intestinal expression of NF-kappa B/TLR4/TNF-alpha/IL-6 is significantly attenuated in treated groups. Eventually, IHC study illustrated concordant decline in mesenteric expression of HIF-1-alpha/TNF-alpha. Conclusion: Single dose pretreatment with Albendazole could ameliorate inflammatory response and enhance ischemia threshold following induction of MIR injury. More studies would clarify existing causality in this phenomenon.
dc.description.sponsorshipDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences [97-01-30-36808]; Iran National Science Foundation (INSF) [96002757]
dc.description.sponsorshipThe study was supported by a grant from Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences (Grant No: 97-01-30-36808) and Iran National Science Foundation (INSF, Grant No: 96002757).
dc.identifier.doi10.1016/j.biopha.2022.113320
dc.identifier.issn0753-3322
dc.identifier.issn1950-6007
dc.identifier.orcid0000-0002-3595-8353
dc.identifier.orcid0000-0003-2818-4203
dc.identifier.orcid0000-0003-2093-3273
dc.identifier.pmid35752010
dc.identifier.scopus2-s2.0-85132730062
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.biopha.2022.113320
dc.identifier.urihttps://hdl.handle.net/11129/12394
dc.identifier.volume153
dc.identifier.wosWOS:000832820500004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevier
dc.relation.ispartofBiomedicine & Pharmacotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectAlbendazole
dc.subjectIschemia reperfusion injury
dc.subjectInflammation
dc.subjectMesenteric ischemia
dc.titleAlbendazole ameliorates inflammatory response in a rat model of acute mesenteric ischemia reperfusion injury
dc.typeArticle

Files